HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Murphy, T M Articles by Lawler, M Search for Related Content PubMed PubMed Citation Articles by Murphy, T M Articles by Lawler, M

Prostate Cancer Research Group, Institute of Molecular Medicine, Trinity College Dublin, Ireland

(Correspondence should be addressed to T M Murphy, Institute of Molecular Medicine, Trinity Centre, St James's Hospital, Dublin 8, Ireland; Email: murphyth{at}tcd.ie)

It is now well established that cancer cells exhibit a number of genetic defects in the machinery that governs programmed cell death and that sabotage of apoptosis is one of the principal factors aiding in the evolution of the carcinogenic phenotype. A number of studies have implicated aberrant DNA methylation as a key survival mechanism in cancer, whereby promoter hypermethylation silences genes essential for many processes including apoptosis. To date, studies on the methylation profile of apoptotic genes have largely focused on cancers of the breast, colon and stomach, with only limited data available on prostate cancer. Here we discuss the major developments in the field of DNA methylation and its role in the regulation of aberrant apoptosis in prostate cancer. The most significant advances have involved the discovery of apoptotic gene targets of methylation, including XAF1, (fragile histidine triad (FHIT ), cellular retinol binding protein 1 (CRBP1), decoy receptor 1(DCR1), decoy receptor 2 (DCR2 ), target of methylation-induced silenceing 1 (TMS1), TNF receptor superfamily, member 6 (FAS), Reprimo (RPRM) and GLI pathogenesis-related 1 (GLIPR1). These genes are reported to be hypermethylated in prostate cancer and some offer potential as diagnostic and prognostic markers. We also introduce the concept of an ‘apoptotic methylation signature’ for prostate cancer and evaluate its potential in a diagnostic, prognostic and therapeutic setting.

This article has been cited by other articles:

				S. M. Collin, C. Metcalfe, L. Zuccolo, S. J. Lewis, L. Chen, A. Cox, M. Davis, J. A. Lane, J. Donovan, G. D. Smith, et al. Association of Folate-Pathway Gene Polymorphisms with the Risk of Prostate Cancer: a Population-Based Nested Case-Control Study, Systematic Review, and Meta-analysis Cancer Epidemiol. Biomarkers Prev., September 1, 2009; 18(9): 2528 - 2539. [Abstract] [Full Text] [PDF]

				C. Festuccia, G. L. Gravina, A. M. D'Alessandro, P. Muzi, D. Millimaggi, V. Dolo, E. Ricevuto, C. Vicentini, and M. Bologna Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models Endocr. Relat. Cancer, June 1, 2009; 16(2): 401 - 413. [Abstract] [Full Text] [PDF]